- BrandLily
Salt -Ramucirumab injection
Cyramza (ramucirumab) is indicated for the treatment of patients with gastric/GEJ adenocarcinoma, NSCLC and mCRC.
CYRAMZA (ramucirumab): Indications for Use
Ramucirumab is a human VEGFR-2 antagonist indicated:
-
as a single agent or in combination with paclitaxel, for treatment of advanced gastric or GEJ adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. 1
-
in combination with docetaxel, for treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy. 1
-
Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab. 1
-
-
in combination with FOLFIRI, for the treatment of mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.